facilitate rapid implementation of the intervention in large numbers of patients by the clinical staff at different institutions, all in the chaos of emergency departments; and to avoid potential responder bias in the outcome assessments of patients (or surrogates) who may have thought they had received "nonstandard" care. Our decision to view the matter of head position as involving "low risk" was based on several considerations: the insufficient amount of level 1 evidence specifying the benefits and harms of head positioning for patients with acute stroke; the fact that people change their head position within the ranges being tested during routine hospital care and in daily life, as they shift from activity during the day to rest and sleep at night; and the view that patient care would not be compromised by either of the interventions.
Finally, Taito and Yamauchi raise an important point regarding an unresolved issue that should be addressed in another trial -that of the appropriate timing (and intensity) of early mobilization after acute stroke that follows from the unexpected results of the AVERT trial. 2 Unfortunately, we did not collect data on the specific time that patients began to move outside the confines of the bed. Craig S. Anderson, Ph.D. 
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Transplanting HCV-Infected Kidneys into Uninfected Recipients
To the Editor: Goldberg et al. (June 15 issue) 1 report cure of hepatitis C virus (HCV) infection, after transplantation of kidneys infected with HCV (genotype 1) into HCV-negative recipients, with the use of a 12-week course of elbasvirgrazoprevir. However, data on other types of solid-organ transplantation are lacking. Here, we report cure of HCV infection after accidental transmission of HCV from one organ donor to five different recipients ( Table 1 ). The 55-year-old female donor did not belong to a group considered to be at high risk for HCV infection, and routine testing for anti-HCV IgG was negative. However, retrospective analysis revealed lowlevel HCV RNA (genotype 1a) viremia. All the transplant recipients were HCV-negative before transplantation and had development of HCV viremia in the early post-transplantation period. A 12-week course of different sofosbuvir-based anti-HCV regimens 2-4 was used to treat four of the patients. The liver-transplant recipient died from septic shock early after transplantation, before treatment could have been initiated. All four recipients who received treatment currently have stable graft function and cure of HCV infection (sustained virologic response at week 12 after treatment).
In summary, we contribute further evidence that the early initiation of a sofosbuvir-based regimen is an efficient and safe treatment option in the context of different types of solidorgan transplantation from an HCV-positive donor to an HCV-negative recipient. 
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To the Editor: Goldberg and colleagues demonstrated that HCV-positive kidneys can be successfully used for transplantation in HCV-negative recipients. Likewise, the livers of many HCV-positive donors are of good quality and can be transplanted, with outcomes similar to those obtained with HCV-negative livers. In 2015, however, 11% of procured HCV-positive livers were discarded. 1 The new direct-acting antiviral agents have dramatically changed the landscape of HCV treatment, with sustained virologic response rates of up to 95%, independent of HCV genotype, stage of fibrosis, or previous response to antiviral therapy. 2, 3 The use of HCV-positive livers could substantially decrease waiting time and mortality among HCV-negative patients on the transplant waiting list. Clinical trial data on intentional transplantation of HCV-positive livers into HCVnegative recipients are lacking. HCV-negative patients who have, without the knowledge of the physician, received HCV-positive livers have had good responses to treatment. 4 In our center, we have successfully performed two intentional transplantations of HCV-positive livers into HCV-negative recipients. In light of the new HCV treatment options available, it is unethical to let HCV-negative patients die while many usable HCV-positive 
